Riluzole and ranolazine application of prostate cancer: Cancer related testicular andliver tissue damage

Köroğlu P., Bugan Gül İ.

Experimental Biomedical Research, vol.5, no.1, pp.10-22, 2022 (Peer-Reviewed Journal) identifier


Aim: In this study, utilizing the in vivo Copenhagen rat model possessing prostate cancer, we studied the possible impact of tumorigenesis on testes and liver morphology and whether riluzole (RIL) and ranolazine (RNL) treatment would have any affect or not. Method: Male Copenhagen rats were divided into four groups: 1) Control group, 2) Cancer group, 3) Cancer + 10 μM Riluzole 4), and Cancer + 2.5 μM / 5 μM Ranolazine group. The tissue samples of testes and liver were taken and processed for light microscopy, including staining with hematoxylin and eosin. Results: In the cancer group, degenerated seminiferous tubules, cell remnants in the lumen were shown in the testis, and a decrease in the spermatogenic cell line was found. The deterioration in these parameters was milder in the treatment groups and an increase in the number of normal tubules was found. In the cancer group, pyknotic nucleus, mononuclear cell infiltration, hyperemia, vacuolization, disrupted arrangement of hepatocyte plates, sinusoidal dilatations, and degenerated hepatocytes were observed in the liver. However, there was a slight damage in cancer + 10 μM RIL, cancer + 2.5 μM RNL, and cancer + 5 μM RNL groups. Properly hepatocyte arrangement and sinusoidal enlargement were observed. Conclusions: This treatment can be considered a promising protective adjuvant candidate for testes and liver tissue in prostate cancer or cancer therapy-related damage.